More than 30 years of experience in global drug development, gene/cell therapy medicines, biological drugs, and rare diseases at different biotech/biopharma companies, including Shanghai Henlius Biotech, Spark Therapeutics (acquired by Roche), Biogen, Bayer HealthCare, and others of progressive responsibilities.

Proven track record of 250+ cumulative sum of IND, NDA/BLA, and MAA submissions in North/South Americas, Europe, India, South Africa, Brazil, Argentina (ISBA) and APAC, leading to the participation in the development of 21 approved products from clinical development to marketing approval and launch.

Has been published more than 100 book chapters and scientific papers in highly-regarded peer-reviewed journals, including New England Journal of Medicine, Nature Medicine, Nature, Cell, Science, and Blood.

Holds an M.B.A. from Harvard Business School, received Ph.D. in Neuroscience and certified in clinical research from the University of California-San Francisco Medical School.

More than 10 years of preclinical development and translational science experience in animal disease modeling development and validation, gene editing tool optimization, viral vector engineering & design, and production process development. 

Successfully led more than 10 drug discovery programs, 6 preclinical pipelines, and 20+ AAV capsid screening programs and received awards such as “Outstanding Innovation and Entrepreneurial Talent” in Zhangjiang National Innovation Demonstration Zone.

Prior to founding HuidaGene, Linyu served as Head of Animal Facility at Shanghai Institute of Organic Chemistry (SIOC) and Head of Gene Editing Facility at the Center for Excellence in Brain Science and Intelligence Technology (CEBSIT) of the Chinese Academy of Sciences (CAS)

Holds an Ph.D. in Developmental Biology from Shanghai Institute of Biochemistry of the Chinese Academy of Sciences and a B.S. in Biotechnology from Nanjing University.

Over 30 years of biotechnology experience with 20+ years of Cell and Gene Therapy research and leadership experience across gene editing platforms (ZFNs, TALENs, and CRISPR), including leadership roles at CRISPR Therapeutics (Head of Genome Editing) and Excision BioTherapeutics (Chief Scientific Officer).

Established track record developing assays and bioinformatics to measure intended and possible unintended editing for research and clinical settings, including developing the Surveyor gene editing assay, establishing ddPCR for gene editing, and developing advanced sequencing and bioinformatics methods for multiplex, in vivo gene editing.

Co-authored highly cited publications in top-tier journals, including Nature Biotechnology, Proceedings of the National Academy of Sciences (PNAS), Nucleic Acids Research, Molecular Therapy, and The CRISPR Journal.

Undergraduate Life Sciences degree from M.I.T., an M.A. in Immunology from the University of California, San Francisco, and a PhD in Molecular and Cell Biology from the University of Iowa.

>30 years of experience in drug discovery, biomedical research,  translational medicine and global drug development from bench to approval.

Responsible for the Company’s day-to-day operations, strategic pipeline portfolio management, and clinical medical and affairs.

Led over 30 product developments in oncology and participated in over 7 approved products in China, the USA, the European Union, Australia, and Japan.

Managed over 3B RMB annual R&D operating capital and a team of over 350 clinical members.

Participated in the successful IPO in the Stock Exchange of Hong Kong (HKEX) with a market value $1.1B USD.

M.S. in Molecular Biology and Biochemistry from the University of Texas Health Science Center at Houston, Graduate School of Biomedical Sciences; MD in Surgery from Norman Bethune University of Medical Sciences at Jilin.

Over 15 years of experience in accounting, auditing, and investment banking, corporate financing, IPO, general financing, investor relation, tax planning, and M&A in China, US Top 4 public accounting firms and pharmaceutical companies. 

With deep involvement in pharmaceutical and capital market industries, Alex was VP of Finance and Secretary of the Board of Directors at Tasly Biopharma focusing on Corporate Finance, IPO project, Internal Control and Compliance, Corporate Governance, Investor Relationship and Public Relationship prior to joining HuidaGene.     

Has served in several domestic and multinational companies such as General Electric, KPMG International, PricewaterhouseCoopers US, PingAn Securities Investment and Tenry Pharm.  Holds an E.M.B.A. in Finance from Shanghai Advanced Institute of Finance (SAIF) at Shanghai Jiao Tong University and obtained dual B.B.A. degrees in Marketing and Accounting from the Shanghai University of Finance and Economics.

Over 10 years of research and industry experiences with deep knowledge in company creation, strategic alliances management, and technology licensing. 

Deep engagement in the venture capital investment for gene therapy and cell therapy companies including Citryll BV, Acrigen Biosciences, and DNAlite Therapeutics.

Prior to joining HuidaGene, Xixi was VP of Business Development at DNALite Therapeutics and analyst positions at several capital partner organizations.

Holds M.Phil (MS) degree in Genetics and MPhil in Bioscience Enterprise (M.B.E) from the University of Cambridge with research experience in Bioengineering and Genetics from Imperial College London and University of Cambridge.